CC
AEON icon

Covalis Capital’s AEON Biopharma AEON Stock Holding History

Covalis Capital’s Portfolio AEON Stock Details AEON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,736
Closed -$1.22M – 81
2021
Q4 		$1.22M Hold
1,736
– – 0.44% 31
2021
Q3 		$1.22M Hold
1,736
– – 0.28% 47
2021
Q2 		$1.2M Buy
+1,736
New +$1.21M 0.39% 42

Other funds holding AEON

ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Covalis Capital's AEON Position: Q1 2022 in Review

Covalis Capital sold out of AEON Biopharma (AEON) in Q1 2022, closing a stake of 1,736 shares — an estimated $1.22M sold.

Covalis Capital first reported a position in AEON in Q2 2021 and held it in 3 quarters. The position peaked at $1.22M in Q3 2021. 71 funds tracked by Wall St. Rank hold AEON as of Q1 2022.

  • Covalis Capital reported no remaining AEON Biopharma position as of Q1 2022 after selling out during the quarter.
  • Covalis Capital sold 1,736 AEON Biopharma shares in Q1 2022, an estimated $1.22M.
  • Covalis Capital first reported a position in AEON Biopharma in Q2 2021 and held it in 3 quarters.
  • Covalis Capital's AEON Biopharma position peaked at $1.22M in Q3 2021.
  • 71 funds tracked by Wall St. Rank held AEON Biopharma as of Q1 2022.

Based on Covalis Capital's 13F filing for Q1 2022, filed 16 May 2022.